A new study, published in Alimentary Pharmacology and Therapeutics, sought to test antigenic comparability between the reference infliximab and the biosimilar.
All monoclonal antibodies have the potential to evoke anti-drug antibodies (ADAs) in patients, and these products can have multiple quality attributes that can impact the immunogenicity, and therefore efficacy, of the drug product. While treatment with reference infliximab (Remicade) and its biosimilar, CT-P13 (Inflectra, Remsima), resulted in similar rates of ADAs in patients who received the drugs in 2 pivotal clinical trials, only limited data are available related to cross‐immunogenicity of reference infliximab and CT‐P13.
A new study, published in Alimentary Pharmacology and Therapeutics, sought to test antigenic comparability between the reference infliximab and the biosimilar. The researchers included the sera of patients with inflammatory bowel disease (IBD) who were treated with the biosimilar or the reference infliximab; they assessed 42 ADA-positive sera samples from patients with IBD who had been treated with the biosimilar for 9 months or more to determine whether the ADAs to CT-P13 would cross-react with 5 different batches of reference infliximab.
They found that all 42 ADA-positive samples of sera reacted to CT-P13 and also reacted to all 5 batches of the reference, and similar antibody cross-reactivity was present in sera from patients who had previous infliximab exposure and in those who were naïve to anti—tumor necrosis factor (anti-TNF) therapy.
Additionally, the researchers measured immunoglobulin G4 activity (IgG4) against 5 batches of the biosimilar and 5 batches of the reference drug. The results showed a similar response of IgG4 against all batches of both products.
“Our findings indicate that sera from IBD patients who developed anti‐CT‐P13 antibodies are cross‐reactive with infliximab,” conclude the authors, adding that, “Interestingly, we observed no difference in the concentration of IgG4 [ADAs] whether the patients were anti‐TNF naïve or infliximab‐experienced patients. Therefore, no specific long‐term immunity was developed to infliximab and exacerbated to CT‐P13 after the switch.”
They add that switching between these products is unlikely to elicit different ADAs, and say that “These data point toward a safe switching between the [2] drugs in ADA‐negative patients.”
Reference
Goncalves J, Santos M, Acurcio R, et al. Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. [Published online June 5, 2018.] Aliment Pharmacol Ther. doi: 10.1111/apt.14808.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.